Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

278
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
278
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

790
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
790
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

729
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
729
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

825
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
825

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.

Nature cardiovascular research·2026
Same author

Co-translational profiling in the cardiac endothelium in response to LPS-induced inflammation in female mice in vivo: a proof-of-concept approach.

Molecular and cellular biochemistry·2026
Same author

Rational discovery of therapeutic PAK1 allosteric activators.

Cell·2026
Same author

Signaling pathway alterations in hearts of a porcine model harboring a β-myosin heavy chain (MYH7-R403Q) gene variant.

Journal of molecular and cellular cardiology plus·2025
Same author

A new era of understanding of the control of thick filament states in the heartbeat.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Unfolded von Willebrand factor binds protein S and reduces anticoagulant activity.

Blood vessels, thrombosis & hemostasis·2025

Related Experiment Video

Updated: Jan 22, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K

Interventricular differences in myofilament function in experimental congestive heart failure.

Rashad J Belin1, Marius P Sumandea, Gail A Sievert

  • 1Department of Physiology & Biophysics, Center for Cardiovascular Research, University of Illinois at Chicago, IL, USA.

Pflugers Archiv : European Journal of Physiology
|September 20, 2011
PubMed
Summary

Congestive heart failure (CHF) depresses right ventricular (RV) myofilament function via increased protein kinase C-alpha (PKC-α) signaling. Left ventricular (LV) myofilament dysfunction is more severe than RV dysfunction in CHF.

More Related Videos

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.8K
Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling
08:29

Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling

Published on: August 1, 2016

9.9K

Related Experiment Videos

Last Updated: Jan 22, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.8K
Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling
08:29

Assessment of Myofilament Ca2+ Sensitivity Underlying Cardiac Excitation-contraction Coupling

Published on: August 1, 2016

9.9K

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Heart Failure Pathophysiology

Background:

  • Congestive heart failure (CHF) leads to significant alterations in cardiac myofilament function.
  • Interventricular differences in myofilament response to CHF are not fully understood.
  • Understanding these differences is crucial for developing targeted therapies.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying interventricular differences in myofilament function during experimental congestive heart failure (CHF).
  • To investigate the role of protein kinase C-alpha (PKC-α) signaling and myofilament protein phosphorylation in CHF-induced myofilament dysfunction.

Main Methods:

  • Induction of CHF in rats via chronic aortic banding or myocardial infarction.
  • Mechanical isolation and Triton-skinning of right ventricular (RV) and left ventricular (LV) myocytes.
  • Assessment of myofilament force-[Ca(2+)] relations, protein phosphorylation (ProQ diamond staining), PKC-α expression/activation, and cardiac troponin I/T (cTnI/cTnT) phosphorylation via immunoblotting.

Main Results:

  • Failing RV myocytes showed decreased maximal force (Fmax) without altered Ca(2+) sensitivity (EC50).
  • Failing LV myocytes exhibited decreased Fmax and increased EC50, indicating reduced Ca(2+) sensitivity.
  • Increased PKC-α expression and activation were observed in failing RV and LV myocardium, with higher levels in the LV.
  • Greater phosphorylation of cTnI and cTnT was found in failing LV myofilaments compared to RV.

Conclusions:

  • RV myofilament function is depressed in experimental CHF, associated with increased PKC-α signaling and myofilament phosphorylation.
  • Myofilament dysfunction is more pronounced in the LV than the RV in CHF, partly due to elevated PKC-α activation and cTnI/cTnT phosphorylation.
  • These findings highlight interventricular molecular differences contributing to myofilament dysfunction in heart failure.